Free Trial

Fresenius SE & Co. (OTCMKTS:FSNUY) Hits New 52-Week High - Still a Buy?

Fresenius SE & Co. logo with Medical background

Key Points

  • Fresenius SE & Co. shares reached a new 52-week high of $13.72, with the last trading price at $13.60.
  • Morgan Stanley has reaffirmed an "overweight" rating on the stock, with an overall average rating of "Buy" among analysts.
  • The company recently raised its dividend to $0.1827, resulting in a dividend yield of 148.0%, with a payout ratio of 33.96%.
  • Looking to export and analyze Fresenius SE & Co. data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Shares of Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.72 and last traded at $13.60, with a volume of 8529 shares changing hands. The stock had previously closed at $13.63.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley reaffirmed an "overweight" rating on shares of Fresenius SE & Co. in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to MarketBeat, Fresenius SE & Co. currently has an average rating of "Buy".

Check Out Our Latest Report on FSNUY

Fresenius SE & Co. Stock Performance

The stock has a market capitalization of $30.40 billion, a price-to-earnings ratio of 25.68 and a beta of 0.76. The company's fifty day simple moving average is $12.44 and its 200 day simple moving average is $11.54. The company has a quick ratio of 1.11, a current ratio of 1.43 and a debt-to-equity ratio of 0.50.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.02. The business had revenue of $6.48 billion during the quarter, compared to analysts' expectations of $5.83 billion. Fresenius SE & Co. had a return on equity of 9.33% and a net margin of 5.09%. On average, equities research analysts expect that Fresenius SE & Co. will post 0.79 earnings per share for the current year.

Fresenius SE & Co. Increases Dividend

The firm also recently announced a dividend, which was paid on Wednesday, June 4th. Stockholders of record on Wednesday, May 28th were given a $0.1827 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Fresenius SE & Co.'s previous dividend of $0.17. This represents a dividend yield of 148.0%. Fresenius SE & Co.'s dividend payout ratio (DPR) is presently 33.96%.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fresenius SE & Co. Right Now?

Before you consider Fresenius SE & Co., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. wasn't on the list.

While Fresenius SE & Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines